Darunavir: A nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 9, 2012, Pages 1363-1375

  Robertson, Jaime ^a   Feinberg, Judith ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Antiretroviral therapy; Darunavir; HIV; Protease inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA AMYLASE PANCREAS ISOENZYME; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; GLUCOSE; LOPINAVIR; LOW DENSITY LIPOPROTEIN; RALTEGRAVIR; RITONAVIR; TENOFOVIR; TIPRANAVIR; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE;

ABDOMINAL PAIN; ANOREXIA; ASTHENIA; CHOLESTEROL BLOOD LEVEL; DATA BASE; DIABETES MELLITUS; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INFORMATION PROCESSING; MONOTHERAPY; NAUSEA AND VOMITING; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; STOMACH DISTENSION;

DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; RITONAVIR; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 84861402613     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.681776     Document Type: Review

References (56)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organization (WHO). UNAIDS Report on the Global AIDS Epidemic 2010
2. Department of Health and Human Services (DHSS). Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1-239. Last updated 3/27/2012. Available at: http://www. aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. [Last accessed 4 May 2012]
3. Bristol-Myers Squibb. Sustiva Prescribing Information. December 2011. http://www.accessdata.fda.gov/ scripts/cder/drugsatfda/. [Last accessed 4 May 2012]
4. Fundaro C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002;16:299-300
5. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry international interim report for 1 January 1989 - 31 July 2011. December 2011; http://www. APRegistry.com. [Last accessed 5 April 2012]
6. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374:796-806
7. Malan DR, Krantz E, David N, et al. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 2008;47:161-7
8. Zhu L, Persson A, Mahnke L, et al. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects. J Clin Pharmacol 2011;51:368-77
9. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ ritonavir versus twice-daily lopinavir/ ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008;372:646-55
10. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010;53:323-32
11. Elgadi MM, Piliero PJ. Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial. Drugs R D 2011;11:295-302
12. Ghosh A, Dawson Z, Mitsuya H. Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. Bioorg Med Chem 2007;15:7576-80
13. Darunavir [package insert], version 8.0. Tibotec Therapeutics. Darunavir Prescribing Information. December, 2011; http://www.accessdata.fda.gov/ scripts/cder/drugsatfda/. [Last accessed 15 Jan 2012]
14. Gyseghem E, Stokbroekx S, de Armas H, et al. Solid state characterization of the anti-HIV drug TMC 114: interconversion of amorphous TMC114, TMC114 ethanolate and hydrate. Eur J Pharm Sci 2009;38:489-97
15. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005;49:2314-21
16. Cahn P. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients [ODIN; TMC114-C229]. AIDS 2011;25:929-39
17. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ ritonavir in treatment-naive HIV-1-infected patients at week 48 [ARTEMIS; TMC114-C211]. AIDS 2008;22:1389-97
18. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir/ ritonavir compared with that of lopinavir/ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial [TITAN; TMC114-C214]. Lancet 2007;370:49-58
19. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1 [POWER 1; TMC114-C213]. AIDS 2007;21:395-402
20. Haubrich R, Berger D, Chiliade P, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients [POWER 2; TMC114-C202]. AIDS 2007;21(6):F11-18
21. Sekar V, Kestens D, Spinosa-Guzman S, et al. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers. J Clin Pharmacol 2007;47:479-84
22. Rachlis A, Clotet B, Baxter J, et al. Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3. HIV Clin Trials 2007;8:213-20
23. Blanche S, Bologna R, Cahn P, et al. Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents. AIDS 2009;23:2005-13
24. Scholler-Gyure M, Kakuda TN, Sekar V, et al. Pharmacokinetics of darunavir/ ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther 2007;12:789-96
25. DeJesus E, Lalezari JP, Osiyemi OO, et al. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults. Antivir Ther 2010;15:711-20
26. Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother 2008;61:769-73
27. Boffito M, Jackson A, Amara A, et al. Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 h following drug cessation. Antimicrob Agents Chemother 2011;55:4218-23
28. Nelson M, Girard PM, Demasi R, et al. Suboptimal adherence to darunavir/ ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data. J Antimicrob Chemother 2010;65:1505-9
29. De Meyer SM, Spinosa-Guzman S, Vangeneugden TJ, et al. Efficacy of once-daily darunavir/ritonavir 800/ 100 mg in HIV-infected, treatment- experienced patients with no baseline resistance-associated mutations to darunavir. J Acquir Immune Defic Syndr 2008;49:179-82
30. Clotet B, Bellos N, Molina J-M, et al. Efficacy and safety of darunavir/ritonavir at week 48 in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169-78
31. Pozniak A, Opravil M, Beatty G, et al. Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors intreatment-experienced HIV type 1-infected patients: POWER 1 and 2. AIDS Res Hum Retroviruses 2008;24:1275-80
32. Arasteh K. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther 2009;14:859-64
33. Molina J-M, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J AIDS 2007;46:24-31
34. De Meyer S, Vangeneugden T, Van Baelen B, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 2008;24:379-88
35. Banhegyi D, Katlama C, Da Cunha C, et al. Phase III TITAN week 96 final analysis: efficacy/ safety of darunavir/ritonavir versus lopinavir/ritonavir in lopinavir/ritonavirnaive, treatment-experienced patients. 9th International Congress on Drug Therapy in HIV Infection; 9 - 13 November 2008; Glasgow, UK
36. De Meyer S, Lathouwers E, Dierynck I, et al. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. AIDS 2009;23:1829-40
37. Hill A, Marcelin AG, Calvez V. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ ritonavir and darunavir/ritonavir in the TITAN trial. HIV Med 2009;10:620-6
38. De Meyer S, Hill A, Picchio G, et al. Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ ritonavir or lopinavir/ritonavir in the TITAN trial. J Acquir Immune Defic Syndr 2008;49:563-4
39. Katlama C, Clotet B, Mills A, et al. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther 2010;15:1045-52
40. Trottier B, Di Perri G, Madruga JV, et al. Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and 2. HIV Clin Trials 2010;11:175-85
41. Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009;23:2289-300
42. Currier J, Averitt Bridge D, Hagins D, et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med 2010;153:349-57
43. Currier JS, Martorell C, Osiyemi O, et al. Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks. AIDS Patient Care STDS 2011;25:333-40
44. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009;23:1679-88
45. De Meyer S, Hill A, De Baere I, et al. Effect of baseline susceptibility and on-treatment mutations on TMC114 and control protease inhibitor efficacy: preliminary analysis of data from protease inhibitor-experienced patientsfrom POWER 1 and POWER 2 [abstract 157]. 13th Conference on Retroviruses and Opportunistic Infections; 5 - 9 February 2006; Denver, CO, USA
46. De Meyer S, Vangeneugden T, Lefebvre E, et al. Phenotypic and genotypic determinants of TMC114 (darunavir) resistance: POWER 1, 2 and 3 pooled analysis. 8th International Conress on Drug Therapy in HIV Infection; 12 - 16 November 2006; Glasgow, Scotland. Abstract No. P196.
47. Arribas JR, Horban A, Gerstoft J, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010;24:223-30
48. Pulido F, Arribas JR, Hill A, et al. Analysis of drug resistance during HIV RNA viremia in the MONET trial of darunavir/ritonavir monotherapy. Antivir Ther 2011;16:59-65
49. Clumeck N, Rieger A, Banhegyi D, et al. 96 week results from the MONET trial: a randomized comparison of darunavir/ ritonavir with versus without nucleoside analogues, for patients with HIV RNA < 50 copies/mL at baseline J. Antimicrob. Chemother. 2011 66 1878-1885
50. Lambert-Niclot S, Flandre P, Valantin MA, et al. Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy. J Infect Dis 2011;204:1211-16
51. Katlama C, Valantin MA, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010;24:2365-74
52. European Medicines Agency. 2011. Available from: http://www.ema.europa. eu/ema/index.jsp
53. Valantin MA, Lambert-Niclot S, Flandre P, et al. Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study. J Antimicrob Chemother 2011
54. US Food and Drug Administration. 2011.Available from: http://www.fda.gov/ Drugs/InformationOnDrugs/default.htm
55. Hill A, Moyle G. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med 2007;8:259-64
56. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment experienced patients infected with multidrug resistant HIV: results of the ANRS 139 TRIO Trial. Clin Infect Dis 2009;49:1441-9